Avita Medical (NASDAQ:RCEL – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.
Analyst Recommendations
This is a summary of current ratings and target prices for Avita Medical and Pulmonx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
Avita Medical presently has a consensus target price of $16.60, suggesting a potential upside of 2.47%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 155.56%. Given Pulmonx’s higher probable upside, analysts clearly believe Pulmonx is more favorable than Avita Medical.
Institutional and Insider Ownership
27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by company insiders. Comparatively, 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Avita Medical and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avita Medical | -42.65% | N/A | -71.34% |
| Pulmonx | -47.93% | -98.23% | -35.89% |
Risk & Volatility
Avita Medical has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
Valuation & Earnings
This table compares Avita Medical and Pulmonx”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avita Medical | $71.61 million | 7.11 | -$48.59 million | ($1.18) | -13.73 |
| Pulmonx | $90.50 million | 1.44 | -$54.00 million | ($1.01) | -2.97 |
Avita Medical has higher earnings, but lower revenue than Pulmonx. Avita Medical is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
About Avita Medical
AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.
About Pulmonx
Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life. Pulmonx’s primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.
Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.
